CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
40.72
+0.34 (0.83%)
At close: Dec 20, 2024, 4:00 PM
40.95
+0.23 (0.56%)
After-hours: Dec 20, 2024, 7:32 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for CRSP stock have an average target of 76.6, with a low estimate of 48 and a high estimate of 105. The average target predicts an increase of 88.11% from the current stock price of 40.72.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRSP stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 2 | 2 | 2 | 2 | 2 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 19 | 19 | 19 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $86 | Buy | Reiterates | $86 | +111.20% | Dec 20, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $94 | Strong Buy | Maintains | $94 | +130.84% | Dec 10, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $53 | Hold | Reiterates | $53 | +30.16% | Nov 6, 2024 |
| Barclays | Barclays | Hold Maintains $59 → $55 | Hold | Maintains | $59 → $55 | +35.07% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +106.29% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
16.28M
from 371.21M
Decreased by -95.61%
Revenue Next Year
139.72M
from 16.28M
Increased by 758.18%
EPS This Year
-5.30
from -1.94
EPS Next Year
-5.15
from -5.30
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 105.0M | 692.6M | 5.7B | |||
| Avg | 16.3M | 139.7M | 670.1M | |||
| Low | 1.6M | n/a | 19.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -71.7% | 4,153.9% | 3,990.3% | |||
| Avg | -95.6% | 758.2% | 379.6% | |||
| Low | -99.6% | - | -86.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.89 | -3.29 | 8.47 | |||
| Avg | -5.30 | -5.15 | -3.08 | |||
| Low | -6.56 | -6.71 | -7.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.